Next Article in Journal
A Rationally Designed Hsp70 Variant Rescues the Aggregation-Associated Toxicity of Human IAPP in Cultured Pancreatic Islet β-Cells
Next Article in Special Issue
Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?
Previous Article in Journal
Comparative Analysis of Zearalenone Effects on Thyroid Receptor Alpha (TRα) and Beta (TRβ) Expression in Rat Primary Cerebellar Cell Cultures
Previous Article in Special Issue
The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review
Open AccessReview

A New Venue of TNF Targeting

Barriers in Inflammation, VIB Center for Inflammation Research, Ghent, Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium
Mouse Genetics in Inflammation, VIB Center for Inflammation Research, Ghent, Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(5), 1442;
Received: 31 March 2018 / Revised: 25 April 2018 / Accepted: 3 May 2018 / Published: 11 May 2018
(This article belongs to the Special Issue Tumor Necrosis Factor (TNF))
The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-manufactured and highly active molecules with possible off-target effects, followed by protein-based medicines such as antibodies. Conventional antibodies bind a specific protein and are becoming increasingly important in the therapeutic landscape. A very prominent class of biologicals are the anti-tumor necrosis factor (TNF) drugs that are applied in several inflammatory diseases that are characterized by dysregulated TNF levels. Marketing of TNF inhibitors revolutionized the treatment of diseases such as Crohn’s disease. However, these inhibitors also have undesired effects, some of them directly associated with the inherent nature of this drug class, whereas others are linked with their mechanism of action, being pan-TNF inhibition. The effects of TNF can diverge at the level of TNF format or receptor, and we discuss the consequences of this in sepsis, autoimmunity and neurodegeneration. Recently, researchers tried to design drugs with reduced side effects. These include molecules with more specificity targeting one specific TNF format or receptor, or that neutralize TNF in specific cells. Alternatively, TNF-directed biologicals without the typical antibody structure are manufactured. Here, we review the complications related to the use of conventional TNF inhibitors, together with the anti-TNF alternatives and the benefits of selective approaches in different diseases. View Full-Text
Keywords: tumor necrosis factor (TNF); TNF receptor (TNFR); biologicals tumor necrosis factor (TNF); TNF receptor (TNFR); biologicals
Show Figures

Graphical abstract

MDPI and ACS Style

Steeland, S.; Libert, C.; Vandenbroucke, R.E. A New Venue of TNF Targeting. Int. J. Mol. Sci. 2018, 19, 1442.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop